1. AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA. (12th June 2019) Authors: Kim, W.S.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Budde, L.E.; Cheah, C.; Gregory, G.P.; Hong, J.; Ku, M.; Marlton, P.; Matasar, M.; Nastoupil, L.; Panizo, C.; Sehn, L.H.; Tzachanis, D.; Chu, W.; Hernandez, M.G.; Kwan, A.; Li, C.C.; Sison, I. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (June 2017) Authors: Trotman, J.; Opat, S.; Marlton, P.; Gottlieb, D.; Simpson, D.; Cull, G.; Ritchie, D.; Verner, E.; Ratnasingam, S.; Anderson, M.; Wood, P.; Wang, L.; Xue, L.; Hedrick, E.; Huang, J.; Hilger, J.; Seymour, J.F.; Roberts, A.W.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY. (June 2017) Authors: Seymour, J.F.; Opat, S.; Cull, G.; Trotman, J.; Gottlieb, D.; Simpson, D.; Marlton, P.; Anderson, M.; Ku, M.; Ritchie, D.S.; Ratnasingam, S.; Augustson, B.; Kim, W.; Wang, L.; Xue, L.; Hilger, J.; Huang, J.; Hedrick, E.; Roberts, A.W.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (23rd June 2022) Authors: Dimopoulos, M.; Opat, S.; D'Sa, S.; Jurczak, W.; Lee, H.-P.; Cull, G.; Owen, R. G.; Marlton, P.; Wahlin, B. E.; Garcia-Sanz, R.; McCarthy, H.; Mulligan, S.; Tedeschi, A.; Castillo, J. J.; Czyz, J.; Fernandez De Larrea Rodriguez, C.; Belada, D.; Libby, E.; Matous, J.; Motta, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1048 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. (17th June 2021) Authors: Bannerji, R.; Yuen, S.; Phillips, T.; Arthur, C.; Isufi, I.; Marlton, P.; Seymour, J. F.; Corradini, P.; Molinari, A.; Gritti, G.; Emmons, R.; Hirata, J.; Musick, L.; Saha, S.; Croft, B.; Flowers, C. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Practical management of myelofibrosis with ruxolitinib. Issue 12 (December 2015) Authors: Ho, P. J.; Marlton, P.; Tam, C.; Stevenson, W.; Ritchie, D.; Bird, R.; Dunlop, L. C.; Durrant, S.; Ross, D. M. Journal: Internal medicine journal Issue: Volume 45:Issue 12(2015) Page Start: 1221 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗